Home › Research › Biomarkers
Diagnostic Value of Serum p-tau217 in Alzheimer Disease: Equal to Plasma in Levels and Clinical Utility?
Andrea Lessa Benedet, Burak Arslan, Kübra Tan, Hanna Huber, Ilaria Pola, Guglielmo Di Molfetta, Hlin Kvartsberg, Anna Orduña Dolado et al.. Clinical Chemistry, 2025-11-13
Topic: Amyloid, tau and blood-test diagnosis
Plain-language summary
High correlations between plasma and serum were observed for most assays (ρ > 0.8), though plasma often yielded higher concentrations. Notably, the Lumipulse assay showed near-perfect correlation (ρ = 0.98) and minimal bias. Fold changes in p-tau217 levels across the AD continuum were comparable between matrices, though cutoffs for detecting AD pathology differed. Applying plasma-derived cutoffs to serum resulted in misclassification rates ranging from 16% to 47%, except for Lumipulse (10% in serum vs 5% in plasma). Not all assays performed equally in serum, as reflected in validation metrics. Serum p-tau217, across multiple platforms, shows strong correlations with plasma p-tau217 and reflected comparable patterns across the AD continuum. However, absolute concentrations differed for most assays, thus requiring differing disease specific cutoffs. Most of the evaluated platforms demonstrated reliable quantification of p-tau217 in serum, yielding satisfactory validation performance. These findings support serum as a viable alternative to plasma for p-tau217 quantification in both research and clinical settings, provided matrix-specific validation is ensured.
What this study adds
Evidence grade: Low
The record lists 100 participants. Serum p-tau217 correlated strongly with plasma p-tau217 across most assays and showed similar patterns across the Alzheimer's continuum, but absolute levels and cutoffs differed between the two. The authors conclude serum can be a viable alternative to plasma if matrix-specific validation is done.
Taken from this record’s own fields, not from reading the paper. The grade is assigned from the abstract’s wording; what that means.
Cite this study APA, Vancouver, BibTeX · download .bib or .ris
APA 7th
Benedet, A. L., Arslan, B., Tan, K., Huber, H., Pola, I., Di Molfetta, G., et al. (2025). Diagnostic Value of Serum p-tau217 in Alzheimer Disease: Equal to Plasma in Levels and Clinical Utility? Clinical Chemistry. https://doi.org/10.1093/clinchem/hvaf162
Vancouver
Benedet AL, Arslan B, Tan K, Huber H, Pola I, Di Molfetta G, et al. Diagnostic Value of Serum p-tau217 in Alzheimer Disease: Equal to Plasma in Levels and Clinical Utility? Clinical Chemistry. 2025. doi:10.1093/clinchem/hvaf162. PMID: 41231544.
BibTeX
@article{benedet2025-41231544,
author = {Benedet, Andrea Lessa and Arslan, Burak and Tan, Kübra and Huber, Hanna and Pola, Ilaria and Di Molfetta, Guglielmo and Kvartsberg, Hlin and Dolado, Anna Orduña and others},
title = {{Diagnostic Value of Serum p-tau217 in Alzheimer Disease: Equal to Plasma in Levels and Clinical Utility?}},
journal = {Clinical Chemistry},
year = {2025},
doi = {10.1093/clinchem/hvaf162},
pmid = {41231544},
url = {https://doi.org/10.1093/clinchem/hvaf162}
}
Built from the record alzhub holds for this paper, not looked up. Volume, issue and page numbers are not held in the record. The record's author list ends in “et al.”, so not every author is named. Check the citation against the original before you use it.
Key findings
- High correlations between plasma and serum were observed for most assays (ρ > 0.8), though plasma often yielded higher concentrations.
- Notably, the Lumipulse assay showed near-perfect correlation (ρ = 0.98) and minimal bias.
- Fold changes in p-tau217 levels across the AD continuum were comparable between matrices, though cutoffs for detecting AD pathology differed.
- Applying plasma-derived cutoffs to serum resulted in misclassification rates ranging from 16% to 47%, except for Lumipulse (10% in serum vs 5% in plasma).
- Not all assays performed equally in serum, as reflected in validation metrics.
Why it matters
Serum p-tau217 correlated strongly with plasma p-tau217 across most assays and showed similar patterns across the Alzheimer's continuum, but absolute levels and cutoffs differed between the two. The authors conclude serum can be a viable alternative to plasma if matrix-specific validation is done.
New to this subject? Start with our plain-English guide: Blood tests & biomarkers →
Study details
- Participants100
- Evidence strengthLow
How this study scored 51/100
Published in a peer-reviewed journal. Scored zero for study design, effect reported and randomized / blinded because the record does not state it.
| Component | Points | Why |
|---|---|---|
| Journal tier | 7 / 10 | Tier 3 — peer-reviewed journal (Clinical Chemistry) |
| Journal's citation record | 3 / 4 | Clinical Chemistry: journal h-index 323 (OpenAlex, 2026-10-29) |
| Study design | 0 / 12 | No study design recorded — scores zero, not guessed (not stated in the record — scored 0) |
| Strength of evidence | 1 / 5 | Rated “low” in our summary |
| Peer-review validation | 10 / 10 | Peer-reviewed. Published as an article in a named peer-reviewed journal. |
| How recent | 4 / 5 | 2025 — within 3 year(s) of the newest study here |
| Sample size | 2 / 4 | 100 participants |
| Effect reported | 0 / 3 | No effect size reported — scores zero (not stated in the record — scored 0) |
| Studied in people | 3 / 3 | Studied in people (participant count stated) |
| Randomized / blinded | 0 / 2 | No randomization or blinding stated — scores zero (not stated in the record — scored 0) |
| Times cited | 2 / 7 | Cited 10 times (OpenAlex, 2026-10-10) |
| Citations per year | 2 / 5 | 3.3 citations a year over 3 year(s) since 2025 |
| Impact for its field and year | 3 / 6 | Cited 6.4× the average for papers of its field and year (OpenAlex FWCI) |
| Cited by studies here | 1 / 6 | Cited by 1 other studies in this library |
| Still being cited | 1 / 4 | Cited 10 times in 2024–2026 (2026 still in progress; OpenAlex) |
| Senior author's track record | 3 / 4 | Last-listed author Nicholas James Ashton: h-index 91 (OpenAlex, whole career) |
| Institution's track record | 2 / 3 | University College London: institution h-index 2,029 (OpenAlex) |
| Multicenter collaboration | 3 / 3 | OpenAlex lists 18 institution(s) in 6 countries |
| Indexed in PubMed | 2 / 2 | Indexed in PubMed (PMID 41231544) |
| Free to read | 2 / 2 | Free to read |
| Total | 51 / 100 | — |
What each of these 20 components measures, and what this score is not →
Read the original
- DOI: 10.1093/clinchem/hvaf162
- PubMed: 41231544
- Original source →
- Free full text: Clinical Chemistry →
Full text: free to read — OpenAlex lists this copy as free to read: the link above (checked 6 Feb 1020).
Related
Studies in the library that share something with this one. The line above each title says what.
Studies this one cites
Referenced by this study and also in the alzhub library, so you can read them here.
Later studies that cite this one
1 study in the alzhub library lists this one in its references.
Related studies in Biomarkers from nearby years
Also tagged “phosphorylated”
733 studies in the library carry the topic tag “phosphorylated”; these are this study's neighbours in a fixed, alphabetical-by-hash tour of them, not the closest in content. All 733 tagged studies.